|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 29122 |
FusionGeneSummary for PSMB2_DENND6B |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: PSMB2_DENND6B | Fusion gene ID: 29122 | Hgene | Tgene | Gene symbol | PSMB2 | DENND6B | Gene ID | 5690 | 414918 |
| Gene name | proteasome subunit beta 2 | DENN domain containing 6B | |
| Synonyms | HC7-I | AFI1B|FAM116B | |
| Cytomap | 1p34.3 | 22q13.33 | |
| Type of gene | protein-coding | protein-coding | |
| Description | proteasome subunit beta type-2macropain subunit C7-Imulticatalytic endopeptidase complex subunit C7-1multicatalytic endopeptidase complex subunit C7-Iproteasome (prosome, macropain) subunit, beta type, 2proteasome beta 2 subunitproteasome component | protein DENND6BDENN domain-containing protein 6BDENN/MADD domain containing 6Bfamily with sequence similarity 116, member Bprotein FAM116B | |
| Modification date | 20180523 | 20180523 | |
| UniProtAcc | P49721 | Q8NEG7 | |
| Ensembl transtripts involved in fusion gene | ENST00000373237, | ENST00000413817, | |
| Fusion gene scores | * DoF score | 4 X 4 X 3=48 | 3 X 2 X 3=18 |
| # samples | 5 | 3 | |
| ** MAII score | log2(5/48*10)=0.0588936890535686 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(3/18*10)=0.736965594166206 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | |
| Context | PubMed: PSMB2 [Title/Abstract] AND DENND6B [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| TCGA | LD | LIHC | TCGA-BC-A112-01A | PSMB2 | chr1 | 36096875 | - | DENND6B | chr22 | 50750846 | - |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| In-frame | ENST00000373237 | ENST00000413817 | PSMB2 | chr1 | 36096875 | - | DENND6B | chr22 | 50750846 | - |
Top |
FusionProtFeatures for PSMB2_DENND6B |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| PSMB2 | DENND6B |
| Component of the 20S core proteasome complex involved inthe proteolytic degradation of most intracellular proteins. Thiscomplex plays numerous essential roles within the cell byassociating with different regulatory particles. Associated withtwo 19S regulatory particles, forms the 26S proteasome and thusparticipates in the ATP-dependent degradation of ubiquitinatedproteins. The 26S proteasome plays a key role in the maintenanceof protein homeostasis by removing misfolded or damaged proteinsthat could impair cellular functions, and by removing proteinswhose functions are no longer required. Associated with the PA200or PA28, the 20S proteasome mediates ubiquitin-independent proteindegradation. This type of proteolysis is required in severalpathways including spermatogenesis (20S-PA200 complex) orgeneration of a subset of MHC class I-presented antigenic peptides(20S-PA28 complex). {ECO:0000269|PubMed:15244466,ECO:0000269|PubMed:27176742, ECO:0000269|PubMed:8610016}. | Guanine nucleotide exchange factor (GEF) for RAB14. Alsohas some, lesser GEF activity towards RAB35.{ECO:0000269|PubMed:22595670}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Tgene | DENND6B | chr1:36096875 | chr22:50750846 | ENST00000413817 | - | 17 | 20 | 246_373 | 520 | 586 | Domain | cDENN |
| Tgene | DENND6B | chr1:36096875 | chr22:50750846 | ENST00000413817 | - | 17 | 20 | 375_499 | 520 | 586 | Domain | dDENN |
| Tgene | DENND6B | chr1:36096875 | chr22:50750846 | ENST00000413817 | - | 17 | 20 | 43_214 | 520 | 586 | Domain | uDENN |
Top |
FusionGeneSequence for PSMB2_DENND6B |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| >In-frame_PSMB2_ENST00000373237_chr1_36096875_-_DENND6B_ENST00000413817_chr22_50750846_-_161aa MEYLIGIQGPDYVLVASDRVAASNIVQMKDDHDKMFKMSEKILLLCVGEAGDTVQFAEYIQKNVQLYKMRNGYELSPTAAANFTRRNLAD |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| >In-frame_PSMB2_ENST00000373237_chr1_36096875_-_DENND6B_ENST00000413817_chr22_50750846_-_483nt ATGGAGTACCTCATCGGTATCCAAGGCCCCGACTATGTTCTTGTCGCCTCCGACCGGGTGGCCGCCAGCAATATTGTCCAGATGAAGGAC GATCATGACAAGATGTTTAAGATGAGTGAAAAGATATTACTCCTGTGTGTTGGAGAGGCTGGAGACACTGTACAGTTTGCAGAATATATT CAGAAAAACGTGCAACTTTATAAGATGCGAAATGGATATGAATTGTCTCCCACGGCAGCAGCTAACTTCACACGCCGAAACCTGGCTGAC TGTCTTCGGAGTCGGAACATCGAGACCTGGATGAAAGACAAGTCCGAGGTGGAGGTCGTGGACCTGGTCCTGAAACTTCGTGAGAAGCTG GTGCGGGCTCAGGGCCACCAGCTCCCTGTGAAGGAGGCTACGCTGCAGCGGGCACAGCTGTACATCGAGACGGTCATCGGCTCCCTGCCC |
| * Fusion transcript sequences (Full-length transcript). |
| >In-frame_PSMB2_ENST00000373237_chr1_36096875_-_DENND6B_ENST00000413817_chr22_50750846_-_4004nt GGGGAGATTTTACCGAGCAACGTAGGGAAACGGCTGCCTGGCTACCTACCCCTTTTTGACACCCACACGTGCTCGGCACCTTACATACAC TGCGTGATTTTATCCTAAAGCCACTTTTAAAATCTTAGTGTGTAAACAGAGAAACTGGGCGTCACATAAGGCAAGTGACCTGCACAGCCT GCTCCGGAGGAGACCCGTACGATCCCAGAGACAAGCACTGAACATAAGGCACCCGGCGCCGCGCCCGCTTTGCAACCTCTCGCGACAGTT GTACGTCATCCGAGAGCGCCGTGGAAGTCGTGCTGCAGGCGTCGCGCCAATCTTCGCTCTGAGGTGCTGTCTCACCGGTGAGACCTGGAA GCGGGCGAGTCTCGTGCTGTGTCGGACCTGCAGCCCCTGGCCTTCCGCCACCATGGAGTACCTCATCGGTATCCAAGGCCCCGACTATGT TCTTGTCGCCTCCGACCGGGTGGCCGCCAGCAATATTGTCCAGATGAAGGACGATCATGACAAGATGTTTAAGATGAGTGAAAAGATATT ACTCCTGTGTGTTGGAGAGGCTGGAGACACTGTACAGTTTGCAGAATATATTCAGAAAAACGTGCAACTTTATAAGATGCGAAATGGATA TGAATTGTCTCCCACGGCAGCAGCTAACTTCACACGCCGAAACCTGGCTGACTGTCTTCGGAGTCGGAACATCGAGACCTGGATGAAAGA CAAGTCCGAGGTGGAGGTCGTGGACCTGGTCCTGAAACTTCGTGAGAAGCTGGTGCGGGCTCAGGGCCACCAGCTCCCTGTGAAGGAGGC TACGCTGCAGCGGGCACAGCTGTACATCGAGACGGTCATCGGCTCCCTGCCCAAAGACCTGCAGGCTGTCTTGTGCCCTCCCTAGAACAA AGCCAAGGGCCACGGTCCCAGGGCCCTAGGTCTGCCTGAGCCTCCCACTCCCCAGTGGTGGCGGCACTGGGCCAAGCACACGCTCCCCTT CCTTGGCCCCCCGCCCAGACTGCAGGCTCCCCTTCCTGCACCACCATTGTCTCAGCAGTAAAGGCGACATTTGGAACCACAGCATGGCCT TGACCATAGGGGTTCCTCGCAGGCAGAGCCTTGCCTCCTCCTGGGTCCCACCTGGCCTCTGCAGACCTTAGGCTGGGACGGGGGCGGGGA CAGGCTGGGAGCCCTTGCTGATGTGGGTGCGTCTACCGTCTGCCCCTCCCGGTGCCCATCTGTTGGCCCCCGACCCCCCTGCGCTGTGTG TGATGCTTCCCTCAGCCCAACAGGCTGCCCAGGACAGGAGGGACCCTCTCCTGACACAGCCCCCGTCTTGTCTGGGGATGGGAGGCTATT TTGCATATAGTCATCAACTTGAGAAAGGGAGAGACCACTTTGCAGTGTGAAGAGCTCTGCTCACCACCCCTGGTGCTCCTCTGGACACCC ACCTGCTTGGGGCTGTGGTTTGTTGGGAGGTAGGGGTTGGGCAGGGGGCTGTGTGCAGCCCAGCACCTCTGCTAGGAGAGCTGGCTCAGC CTGGCTCTCGGAGAGCCACAGCACCTTCCTGGCTCCCAGTCCTGGAGCCCCCACCAGGCACCAGCTCCGTGCGTCCCTTCTGGGAGGTGG ACAGGGCTCCTGTTGTCCAAGTGTGTCCGTCCATCCCCCACATGCAGCCCAAGGGGCTCTGGACTTCGGCCTGACCCTGCCTCTGGCTGG AGCCTGCATGTCTCCCTTTCCTTGGTAAGGGGTGAACGTCCCTAAGAGCCACCTCTGGGTTGTATGCTCCCCCCGTGACACCTGCAGGCA CTGAGGCCGGTGAGGTACGGTGTTGACCCTGCACAGCACACAGTGACGGTACTGTCAGGGCTCCGGACAGCCAAGCCCTGCTCAGCATCA CGCACTGTGTGCCCGGGAGCAGGTCCCCTGACCACTCAGACCCTCAGACTCCTCATCTGAGCGAGCCAGCCATGCAGATGCCCGACAGGG TGCTGGGAGGGCCACTCATGGAGACTGGGCTTTGTACCCTGTGAGGCCGGGCGGGTGCTGGCCAGGGGACACAGGGCTGGGGGAGGGACT TTTTCTTTTTTTTTCTTTTTGAAATGGAGTCTCGCTCTGTTGCCCAGGCTGGAGTGCAGTGGCATGATCTCGGCTCACTGCAAGCTCTGC CTCCCGGGTTCACGCCATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGGACTACAGGCACCCACCACTGCGCTTGGTTAATTTTTTGTATT TGTAGTAGAGACAGGGTTTCACCATGTTAGCCAGGATGGTCTCGATCTCCTGACCTCGTAATCCGCCCGCCTCGGCCTCCCAACGTGCTA GGATTACAGGCATGAGCCACCGCGCCCGGCCGGGACTTTTCTTTTTCTTCTGAGGCCCCCATTCAGTCCGAGGAATGTAGCCTTCATTCA GCGCAACGTACTGTTTGTGTTCTCATTGGTGCTCTCAGACCTCCAGCCAGGTGGTGGAGAGCGAGCACTGCCAGCCACTTCAGTGCAGGA TGTGACTGAGCCACAAGGACAGCGGGGTCAGGTGTCCGGGCGCCAGGTAGTTCTCAGAACTTGGTACATGTCAACTTGTCCAGCCCAACT GCAGCCCAGGACAGCCTGTCCCTGTTCCCATTCTACAGACAAGACGCGGAGGCAGCCGGGAGGGTGACCAAGGGGAGCTGTTAAGCCCCA GATGTCTGGTGCAGGGTCCAAGGATGTGACCACATGAAACAGAACACATAGAGGCCGAGGTGGCAAACCTGTTCTGTGGCAGGGACAAGC CGGGGACCCGAGGGTGAGAAAGGTCCTGGCCCCAAATGCAGCTTGGGCCTCCTGACTGTAGCACAGGGGGACCAGCCTCCCCACTGAGGG CTTGGTCTCTAGAGGGTCTGCAGAGATGCTGGCACCTCTTGTGTGGGCAGCTTGAATGCTGACCTCCATAAGATGGGGCCTGGGGGGCCA GTACAGGCCCTGCCATCAGCTGCCCTCCACCAGGGCCCTCTGCAAAAGCCTTATGCTGGTGACCAGCCCCCTGAGGACCACCACTTCAAG GTGTCGGGGCAGCTTGGGAAGACAACCCACCTCTCTCACAACTGTGACCCCACTTTGGGGAGCGCACCCCAAGGACCGTGGCAGCATGTG CTTCCCCACAGCACAGTCTCGCCTCACTTGGCTTTCTGAGGGCTGCCGCACAGCACAGAGGGCTGCAGACCCACATGGCTGCAGGGGAGG GGCTTCAGGCTGGTCTCTGAGGAGCCCCCAGGGACCCTGGCCACTGTGTATCCAGAAATGCACAAGCAGATTTCCCTGGAGGGCTCTGGT GAGGCCACATAGTGGCGTGTGAAGGGGGAACTTGAGGGGGGAACCGGGCTGGGTGGCCAGCATTGCCCTGGGCAGAAGCTAAGGCTAAGG TGGGGGGTAGTGTCCCAGCCCCTCTTCCTCAGGGCCTGTCCCCACCTGTGCAGAAGAGGCCTGGGGTGGAATGTGGCCTGGGGTGGATGG GTGGGGGCTGGGCGTGGAGACCTGCCAGCTCCATCTGTCCGGATGCCTCTTGTGGCCCCCCCAGTGTCAGGGCCGCTCTGAGTTGGCTGA GCCTCTGTCCAGGGCTAGGCCATGGCCCTCCCCGCCCCACGCACTCCAGGCCAGGGGCAGTCAGTGAAGAGGCAGGAAGGTCCAGACAGC TCTACCCCTGGCCAGAGTGCCAGCCCCCGCAGGCAAGAGGGCTTGCTGGGCAGAACTTAGTTGGCGAGGGTGAGGACTGCTGTGGTCACA GGCCTCCCGAAGGACAGGGACCACAGAACCTAGAGGGTGGGAAGGGCTGGGAGCAGGTCTGGAGTGGGGCTCGGGGCTGAGGGTGCACAC AGGGGGCCTGCTCAGGGACAGGAAGGACAGCTGCTCACCCTCAAGCTTCCTGCTGGCTATTTAAAGACTCCCTTTTAGTCTAGAACAGTG |
Top |
FusionGenePPI for PSMB2_DENND6B |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| PSMB2 | SLX1B, UBC, PSMA2, RAD23A, PSMA1, PSMB3, FKBP8, UCHL5, POMP, PSMB1, PSMB5, PSMB7, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMB4, PSMB6, PSMB8, PSMC6, PSMC1, PSMC4, PSMC2, PSMC5, PSMD11, PSMD7, PSMD1, PSMD2, PSMD8, PSMD6, PSMC3, PSMD12, PSMD13, PSMD3, PSMD14, PSMD4, PSME1, PSMD5, PSME3, PSMA8, UBA52, RAD23B, TST, UBE2A, PYGB, FOLR1, YBX1, HRAS, SMARCA2, TUBB, C11orf58, PIR, UBE2B, SEC23A, VIM, SULT1A4, FN1, VCAM1, IQCB1, ITGA4, PARK2, GPX2, DDX49, CDK20, HOXA2, PYCRL, ASB11, KRT13, KCTD9, AMFR, SYVN1, PSMB9, HSPB1, AMBRA1, ACACA, ASNA1, ADRM1, MRPS9, PGK1, YWHAE, XPOT, PTEN, MCM2, POU5F1, UBLCP1, PSME4, AKIRIN2, PSMG2, PSME2, PSMF1, FBXO7, PSMG1, CYLD | DENND6B | APP, MAP3K1 |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for PSMB2_DENND6B |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Hgene | PSMB2 | P49721 | DB08889 | Carfilzomib | Proteasome subunit beta type-2 | small molecule | approved|investigational |
Top |
RelatedDiseases for PSMB2_DENND6B |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | PSMB2 | C0005695 | Bladder Neoplasm | 1 | CTD_human |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|